Navigation Links
CoMentis and Anvyl Announce Formation of Alpharmagen, a Joint Venture to explore Nicotinic Modulators
Date:6/14/2013

SOUTH SAN FRANCISCO, Calif., June 14, 2013 /PRNewswire-iReach/ -- CoMentis, Inc. and Anvyl announced today that the companies have agreed to form Alpharmagen, a joint venture committed to discovering and developing novel modulators of the alpha7 nicotinic receptor.

"CoMentis is extremely pleased to be forming Alpharmagen in partnership with Anvyl" said Terence Kelly,Ph.D, CoMentis' President and CEO. "We believe that alpha7 modulators have the potential to become significant therapeutic agents, and we believe that the portfolio of allosteric modulators and the expertise that Anvyl brings provides a unique 2nd generation approach to the established alpha 7 agonist program that CoMentis has advanced."

"We are pleased to be joining forces with CoMentis in creating Alpharmagen" stated David Putman, Anvyl's Chief Operating Officer. The scientific programs are very complimentary and the teams are well matched in terms of their experience. We believe that we can advance compounds quickly into clinical trials."

About Alpha7 Modulators.

The alpha 7 nicotinic acetylcholine receptor is believed to play a role in cognition and modulators of this receptor in the human brain are reported to have shown promise in Phase 2 clinical trials exploring cognitive disorders associated with schizophrenia and Alzheimer's disease.

About CoMentis:


CoMentis, Inc. has its headquarters in South San Francisco. The company is engaged in the discovery and development of small- molecule drugs to treat Alzheimer's disease.

For more information about CoMentis, please visit the Company's website at www.comentis.com


Contacts:
CoMentis: Terence Kelly, President and Chief Executive Officer (650) 869-7600

About Anvyl

Anvyl LLC is based in Irvine, CA and specializes in the development of drugs for serious neurologic and psychiatric disorders. Anvyl's drug discovery approach uses targeted allosteric modulation of ion channels to correct disease.

For more information about Anvyl, please visit the Company's website at: www.anvylllc.com


Anvyl Contact: David Putman, Chief Operating Officer   
(949) 252-9211

Media Contact: daniel hunt CoMentis, 6502106160, dhunt@comentis.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE CoMentis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
3. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
4. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
5. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
6. Misonix Announces New Distribution Agreement For Panama
7. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
8. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
9. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
10. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
11. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com recently ... of Eyeglasses . , Millions of individuals in the United States and Canada ... become a way to both correct vision and make a fashion statement. Even celebrities ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
Breaking Medicine News(10 mins):